Description
This active molecular is a potent and selective D-prostanoid and CRTH2 inhibitor. IC50 values are 8 and 35 nM, respectively in plasma. Vidupiprant as an add-on to inhaled corticosteroid therapy demonstrated no associated risks but was not effective at improving asthma symptoms or lung function in patients with inadequately controlled moderate-to-severe asthma.symptoms or lung function in patients with inadequately controlled moderate-to-severe asthma